PT  - JOURNAL ARTICLE
AU  - Wang, Xiangshi
AU  - Chang, Hailing
AU  - Tian, He
AU  - Li, Jingjing
AU  - Wei, Zhongqiu
AU  - Wang, Yixue
AU  - Xia, Aimei
AU  - Ge, Yanling
AU  - Wang, Jiali
AU  - Liu, Gongbao
AU  - Cai, Jiehao
AU  - Wang, Jianshe
AU  - Zhu, Qirong
AU  - Zhu, Yanfeng
AU  - Zhai, Xiaowen
AU  - Zeng, Mei
TI  - Epidemiological and clinical features of SARS-CoV-2 Infection in children during the outbreak of Omicron Variant in Shanghai, March 7-March 31, 2022
AID  - 10.1101/2022.04.28.22274421
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.28.22274421
4099  - http://medrxiv.org/content/early/2022/05/02/2022.04.28.22274421.short
4100  - http://medrxiv.org/content/early/2022/05/02/2022.04.28.22274421.full
AB  - Objectives To understand the epidemiological and clinical characteristics of pediatric SARS-CoV-2 infection during the early stage of Omicron variant outbreak in Shanghai.Methods This study included local COVID-19 cases <18 years in Shanghai referred to the exclusively designated hospital by the end of March 2022 since emergence of Omicron epidemic. Clinical data, epidemiological exposure and COVID-19 vaccination status were collected. Relative risks (RR) were calculated to assess the effect of vaccination on symptomatic infection and febrile disease.Results A total of 376 pediatric cases of COVID-19 (median age:6.0±4.2 years) were referred to the designated hospital during the period of March 7-31, including 257 (68.4%) symptomatic cases and 119 (31.6%) asymptomatic cases. Of the 307 (81.6%) children;3 years eligible for COVID-19 vaccination, 110 (40.4%) received 2-dose vaccines and 16 (4.0%) received 1-dose vaccine. The median interval between 2-dose vaccination and infection was 3.5 (IQR: 3, 4.5) months (16 days-7 months). Two-dose COVID-19 vaccination reduced the risks of symptomatic infection and febrile disease by 35% (RR 0.65, 95% CI:0.53-0.79) and 33% (RR 0.64, 95% CI: 0.51-0.81). Two hundred and sixteen (83.4%) symptomatic cases had fever (mean duration: 1.7±1.0.8 days), 104 (40.2%) had cough, 16.4% had transient leukopenia; 307 (81.6%) had an epidemiological exposure in household (69.1%), school (21.8%) and residential area (8.8%).Conclusion The surge of pediatric COVID-19 cases and multiple transmission model reflect wide dissemination of Omicron variant in the community. Asymptomatic infection is common among Omicron-infected children. COVID-19 vaccination can offer protection against symptomatic infection and febrile disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Science and Technology Commission of Shanghai Municipality (NO. 20JC141020002), the Key Development Program of Children's Hospital of Fudan University (EK2022ZX05), the Three-Year Action Plan for Strengthening the Construction of Public Health System in Shanghai (2020-2022) (GWV-3.2), and the Key Discipline Construction Plan from Shanghai Municipal Health Commission (GWV-10.1-XK01). None of the funding organizations played any role in the trial design, data collection, analysis of results, or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Children's Hospital of Fudan University waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the present study are available from the corresponding author upon reasonable request